40794-72-7

Usage

Uses

Used in Organic Synthesis:
(2Z)-but-2-ene-1,4-diamine serves as a valuable building block in organic synthesis, contributing to the formation of a wide range of chemical compounds. Its unique structure allows for versatile reactions and the creation of diverse molecules with various applications.
Used in Pharmaceutical Production:
As a component in the production of pharmaceuticals, (2Z)-but-2-ene-1,4-diamine plays a crucial role in the development of new drugs. Its presence in these compounds can contribute to their efficacy and therapeutic potential.
Used in Chemical Compounds Production:
(2Z)-but-2-ene-1,4-diamine is also utilized in the production of other chemical compounds, expanding its applications beyond the pharmaceutical industry. Its versatility in bonding and reacting with other molecules makes it a valuable asset in the synthesis of various chemical products.
Used in Medicinal Applications:
Owing to its biological activity, (2Z)-but-2-ene-1,4-diamine is being studied for potential medicinal applications. Researchers are exploring its properties to understand how it can be harnessed to develop new treatments and therapies for various health conditions.

Upstream product

• 40794-71-6 cis-1,4-diphthalimido-but-2-ene 

Downstream Products

• 72331-40-9 1,3,4,7-tetrahydro-2H-1,3-diazepin-2-one 
• 167845-56-9 (Z)-(4-aminobut-2-en-1-yl) tert-butyl carbamate 
• 215167-64-9 (4-(tert-butoxycarbonylamino)but-2-enyl)carbamic acid tert-butyl ester 
• 1080018-80-9 ((Z)-4-phenoxycarbonylamino-but-2-enyl)-carbamic acid phenyl ester 

Relevant academic research and scientific papers

Synthesis method and application of tert-butyloxycarbonyl-protected ammonia compound

The invention relates to a synthesis method and application of a tert-butoxycarbonyl protected ammonia compound, in particular to a novel synthesis method of a compound represented by the formula (I).

Further studies on bis-charged tetraazacyclophanes as potent inhibitors of small conductance Ca2+-activated K+ channels

Previously, quinolinium-based tetraazacyclophanes, such as UCL 1684 and UCL 1848, have been shown to be extraordinarily sensitive to changes in chemical structure (especially to the size of the cyclophane system) with respect to activity as potent non-peptidic blockers of the small conductance Ca 2+-activated K+ ion channels (SKCa). The present work has sought to optimize the structure of the linking chains in UCL 1848. We report the synthesis and SKCa channel-blocking activity of 29 analogues of UCL 1848 in which the central CH2 of UCL 1848 is replaced by other groups X or Y = O, S, CF2, CO, CHOH, CC, CHCH, CHMe to explore whether subtle changes in bond length or flexibility can improve potency still further. The possibility of improving potency by introducing ring substituents has also been explored by synthesizing and testing 25 analogues of UCL 1684 and UCL 1848 with substituents (NO2, NH2, CF 3, F, Cl, CH3, OCH3, OCF3, OH) in the 5, 6 or 7 positions of the aminoquinolinium rings. As in our earlier work, each compound was assayed for inhibition of the afterhyperpolarization (AHP) in rat sympathetic neurons, an action mediated by the SK3 subtype of the SK Ca channel. One of the new compounds (39, R7 = Cl, UCL 2053) is twice as potent as UCL 1848 and UCL 1684: seven are comparable in activity.